Table 3 Patients’ characteristics by the presence of albuminuria and by age groups
From: Diabetic kidney disease in the elderly: prevalence and clinical correlates
< 65 years | 65–75 years | > 75 years | |||||||
|---|---|---|---|---|---|---|---|---|---|
ALB- | ALB+ | ALB- | ALB+ | ALB- | ALB+ | ||||
n = 43,352 | n = 14,886 | p | n = 40,556 | n = 16,126 | p | n = 28,300 | n = 14,375 | p | |
Male sex | 25,532 (58.9%) | 10,409 (69.9%) | < 0.001 | 21,651 (53.4%) | 10,818 (67.1%) | < 0.001 | 12,721 (45.0%) | 8159 (56.8%) | < 0.001 |
Age (years) | 56 ± 7 | 57 ± 7 | < 0.001 | 70 ± 3 | 70 ± 3 | < 0.001 | 80 ± 4 | 81 ± 4 | < 0.001 |
Duration of diabetes (years) | 8 ± 7 | 9 ± 8 | < 0.001 | 12 ± 9 | 13 ± 9 | < 0.001 | 14 ± 11 | 16 ± 11 | < 0.001 |
eGFR < 60 mL/min/1.73m2 | 2086 (4.8%) | 1855 (12.5%) | < 0.001 | 7304 (18.0%) | 5000 (31.0%) | < 0.001 | 11,316 (40.0%) | 7605 (52.9%) | < 0.001 |
Retinopathy | 4346 (10.0%) | 2652 (17.8%) | < 0.001 | 5357 (13.2%) | 3416 (21.2%) | < 0.001 | 3729 (13.2%) | 2750 (19.1%) | < 0.001 |
BMI (Kg/m2) | 30.1 ± 5.7 | 31.1 ± 5.9 | < 0.001 | 29.4 ± 5.1 | 30.0 ± 5.1 | < 0.001 | 28.3 ± 4.7 | 28.5 ± 4.7 | < 0.001 |
HbA1c (%) | 7.2 ± 1.4 | 7.6 ± 1.6 | < 0.001 | 7.1 ± 1.2 | 7.4 ± 1.3 | < 0.001 | 7.1 ± 1.2 | 7.4 ± 1.3 | < 0.001 |
Triglycerides ≥150 mg/dl | 13,144 (32.0%) | 6152 (43.7%) | < 0.001 | 10,438 (27.4%) | 5256 (34.9%) | < 0.001 | 6453 (24.8%) | 4024 (30.7%) | < 0.001 |
HDL < 40/< 50 mg/dL (Male/Female) | 15,038 (37.3%) | 6165 (44.4%) | < 0.001 | 12,114 (32.4%) | 5605 (37.9%) | < 0.001 | 8308 (32.5%) | 4878 (38.0%) | < 0.001 |
LDL ≥100 mg/dL | 21,368 (53.4%) | 6674 (49.1%) | < 0.001 | 17,237 (46.0%) | 6306 (42.8%) | < 0.001 | 12,048 (47.3%) | 5662 (44.2%) | < 0.001 |
Blood Pressure ≥ 140/85 mmHg | 16,778 (45.2%) | 7324 (56.3%) | < 0.001 | 18,392 (53.4%) | 8762 (62.8%) | < 0.001 | 12,690 (55.1%) | 7516 (63.2%) | < 0.001 |
Smokers | 6062 (23.4%) | 2803 (29.9%) | < 0.001 | 2863 (12.9%) | 1572 (16.9%) | < 0.001 | 869 (6.1%) | 624 (8.4%) | < 0.001 |
Cardiovascular therapy | |||||||||
Lipid-lowering treatment | 22,567 (52.1%) | 8835 (59.4%) | < 0.001 | 24,821 (61.2%) | 10,669 (66.2%) | < 0.001 | 15,504 (54.8%) | 8294 (57.7%) | 0.072 |
Treatment with statins | 20,167 (46.5%) | 7835 (52.6%) | < 0.001 | 23,040 (56.8%) | 9888 (61.3%) | < 0.001 | 14,616 (51.6%) | 7796 (54.2%) | 0.217 |
Treatment with fibrates | 1616 (3.7%) | 669 (4.5%) | < 0.001 | 1058 (2.6%) | 445 (2.8%) | 0.045 | 508 (1.8%) | 292 (2.0%) | 0.175 |
Antihypertensive treatment | 24,528 (56.6%) | 10,541 (70.8%) | < 0.001 | 29,651 (73.1%) | 13,380 (83.0%) | < 0.001 | 22,154 (78.3%) | 12,170 (84.7%) | < 0.001 |
Treatment with ACE-Is/ARBs | 21,042 (48.5%) | 9418 (63.3%) | < 0.001 | 25,256 (62.3%) | 11,682 (72.4%) | < 0.001 | 18,282 (64.6%) | 10,141 (70.5%) | < 0.001 |
Aspirin | 6536 (15.1%) | 2931 (19.7%) | < 0.001 | 9751 (24.0%) | 4527 (28.1%) | < 0.001 | 7468 (26.4%) | 4071 (28.3%) | 0.010 |
Antidiabetic therapy | |||||||||
Diet | 2596 (6.0%) | 553 (3.7%) | < 0.001 | 2445 (6.0%) | 641 (4.0%) | < 0.001 | 1502 (5.3%) | 492 (3.4%) | < 0.001 |
Oral antidiabetic drugs | 29,916 (69.0%) | 9234 (62.0%) | < 0.001 | 27,180 (67.0%) | 9199 (57.0%) | < 0.001 | 17,437 (61.6%) | 7569 (52.7%) | < 0.001 |
Oral drugs and insulin | 6320 (14.6%) | 3140 (21.1%) | < 0.001 | 6365 (15.7%) | 3541 (22.0%) | < 0.001 | 4416 (15.6%) | 2852 (19.8%) | < 0.001 |
Insulin | 4520 (10.4%) | 1959 (13.2%) | < 0.001 | 4566 (11.3%) | 2745 (17.0%) | < 0.001 | 4945 (17.5%) | 3462 (24.1%) | < 0.001 |
Q Score | |||||||||
< 15 | 864 (2.0%) | 1670 (11.2%) | < 0.001 | 541 (1.3%) | 1267 (7.9%) | < 0.001 | 449 (1.6%) | 1144 (8.0%) | < 0.001 |
15–25 | 9847 (22.7%) | 5528 (37.1%) | < 0.001 | 8829 (21.8%) | 5618 (34.8%) | < 0.001 | 6948 (24.6%) | 5395 (37.5%) | < 0.001 |
> 25 | 32,641 (75.3%) | 7688 (51.6%) | < 0.001 | 31,186 (76.9%) | 9241 (57.3%) | < 0.001 | 20,903 (73.9%) | 7836 (54.5%) | < 0.001 |